Impact of (68)Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence

In this prospective survey of referring physicians, we investigated whether and how (68)Ga-labeled prostate-specific membrane antigen 11 ((68)Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective surve...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Nucl Med
Päätekijät: Calais, Jeremie, Fendler, Wolfgang P., Eiber, Matthias, Gartmann, Jeannine, Chu, Fang-I, Nickols, Nicholas G., Reiter, Robert E., Rettig, Matthew B., Marks, Leonard S., Ahlering, Thomas E., Huynh, Linda M., Slavik, Roger, Gupta, Pawan, Quon, Andrew, Allen-Auerbach, Martin S., Czernin, Johannes, Herrmann, Ken
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Society of Nuclear Medicine 2018
Aiheet:
Theranostics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5868499/
https://ncbi.nlm.nih.gov/pubmed/29242398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.117.202945
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia